[Preparation and characterization of monoclonal antibody against human uterine cervical carcinoma].
A murine Hybridoma, CEB9, which stably produces monoclonal antibody against human uterine cervical carcinoma is described. CEB9 was obtained by fusing splenic cells from a BALB/c mouse immunized with human uterine cervical carcinoma cell line CC-801 cells with mouse myeloma cell line SP2/0 -Ag14 cells, followed by cloning and subcloning. The antibody is identified as IgG. The results of immunocytochemistry and fluorescence analysis show that the antibody reacted strongly with human uterine cervical carcinoma cells only among the following tested cell lines: PLC/RF/5, 7402, LETP-78, Scle, Hep-2, 2BS, as well as primary cultured human fibroblast cells. Pancreatic carcinoma cells were reactive.
Song
G
G
Institute of Basic Medical Sciences, Beijing.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D000912:Antibodies, Neoplasm / Q000378:metabolism; D005260:Female; D006801:Humans; D006825:Hybridomas / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D009101:Multiple Myeloma / Q000473:pathology; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm